IP Verse

Biontech competitive analysis

Loading summary...

Latest oppositions filed by Biontech

Explore patent oppositions filed by Biontech against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4108671
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMODERNAAug 20, 2025
EP4226941
Pegylated Liposomes For Delivery Of Immunogen-Encoding RnaGLAXOSMITHKLINEJul 22, 2025
EP3981437
Nucleic Acid VaccinesMODERNAJul 9, 2025
EP4023249
Nucleic Acid VaccinesMODERNAJul 9, 2025
EP3853305
High-Purity Peg Lipids And Uses ThereofMODERNAJul 2, 2025
EP3917503
Methods Of Preparing Lipid NanoparticlesMODERNAFeb 6, 2025
EP3283059
Method For Producing Rna CompositionsCUREVACOct 4, 2024
EP4155409
Method Of Increasing The Replication Of A Circular Dna MoleculeCUREVAC MANUFACTURINGSep 25, 2024
EP3389630
Neoantigen Identification, Manufacture, And UseGRITSTONE BIOAug 8, 2024
EP3625345
Modified Messenger Rna Comprising Functional Rna ElementsMODERNAFeb 23, 2024

Latest patents of Biontech opposed by its competitors

Explore Biontech's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3294333
Jul 9, 2025Claudin-18.2-Specific Immunoreceptors And T Cell Epitopes1
EP3294325
Jul 26, 2023Enhancing The Effect Of Car-Engineered T Cells By Means Of Nucleic Acid Vaccination1
EP3892295
Apr 26, 2023Individualized Vaccines For Cancer1
EP3126381
Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell Epitopes1
EP3445850
Oct 27, 2021Methods For Providing Single-Stranded Rna1
EP3473267
Sep 8, 2021Individualized Vaccines For Cancer1
EP2714071
Jul 10, 2019Individualized Vaccines For Cancer3
EP2959021
Aug 8, 2018Methods And Kits For The Molecular Subtyping Of Tumors1

Latest publications and patents of Biontech New

Explore the latest publications and patents granted to Biontech, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Biontech

EP3294333
Jul 9, 2025Claudin-18.2-Specific Immunoreceptors And T Cell EpitopesPatent Maintained As Amended
EP3294325
Jul 26, 2023Enhancing The Effect Of Car-Engineered T Cells By Means Of Nucleic Acid VaccinationGranted And Under Opposition
EP3892295
Apr 26, 2023Individualized Vaccines For CancerOpposition Rejected
EP3126381
Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell EpitopesPatent Maintained As Amended
EP3445850
Oct 27, 2021Methods For Providing Single-Stranded RnaGranted And Under Opposition
EP3473267
Sep 8, 2021Individualized Vaccines For CancerGranted And Under Opposition
EP2714071
Jul 10, 2019Individualized Vaccines For CancerOpposition Rejected
EP2959021
Aug 8, 2018Methods And Kits For The Molecular Subtyping Of TumorsRevoked
EP2386557
Jan 10, 2018Novel Substituted ImidazoquinolinesNo Opposition Filed Within Time Limit

Latest PTAB cases involving Biontech

Discover the latest PTAB cases involving Biontech, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Biontech

IPR2023-01359Aug 28, 2023BIONTECHMODERNAFinal Written Decision - Appealed

Peer Comparison New

IP litigation analysis comparing Biontech with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIONTECH DIAGNOSTICS - 1 - -
JAMES POOLE153 - - -